Preclinical data for MaaT03X, designed to improve response rate to immune checkpoint inhibitors in a solid tumor indication

During the Microbiome Connect Europe conference, held early in July in Amsterdam, Microbiomepost asked Nathalie Corvaïa, Chief Scientific Officer at MaaT Pharma, to give an overview of preclinical and clinical results for MaaT013 and MaaT033, designed by the gutPrint platform, to improve response rate to immune checkpoint inhibitors in a solid tumor indication.